DE69830997D1 - Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten - Google Patents

Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten

Info

Publication number
DE69830997D1
DE69830997D1 DE69830997T DE69830997T DE69830997D1 DE 69830997 D1 DE69830997 D1 DE 69830997D1 DE 69830997 T DE69830997 T DE 69830997T DE 69830997 T DE69830997 T DE 69830997T DE 69830997 D1 DE69830997 D1 DE 69830997D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
compositions containing
containing heavy
different medicaments
gelatin capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69830997T
Other languages
English (en)
Other versions
DE69830997T2 (de
Inventor
L Rocco
M Laughlin
M Franson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/813,946 external-priority patent/US5837714A/en
Priority claimed from US08/808,761 external-priority patent/US5760056A/en
Priority claimed from US08/810,560 external-priority patent/US5776987A/en
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of DE69830997D1 publication Critical patent/DE69830997D1/de
Publication of DE69830997T2 publication Critical patent/DE69830997T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69830997T 1997-03-03 1998-02-27 Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten Expired - Lifetime DE69830997T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US808761 1997-03-03
US08/813,946 US5837714A (en) 1997-03-03 1997-03-03 Solid pharmaceutical dispersions
US08/808,761 US5760056A (en) 1997-03-03 1997-03-03 Pharmaceutical formulation
US813946 1997-03-03
US810560 1997-03-03
US08/810,560 US5776987A (en) 1997-03-03 1997-03-03 Pharmaceutical suspension formulation
US2850498A 1998-02-24 1998-02-24
US28504 1998-02-24
PCT/US1998/004078 WO1998038987A1 (en) 1997-03-03 1998-02-27 Pharmaceutical formulations containing poorly soluble drug substances

Publications (2)

Publication Number Publication Date
DE69830997D1 true DE69830997D1 (de) 2005-09-01
DE69830997T2 DE69830997T2 (de) 2006-02-09

Family

ID=27487679

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830997T Expired - Lifetime DE69830997T2 (de) 1997-03-03 1998-02-27 Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten

Country Status (10)

Country Link
EP (1) EP0996436B1 (de)
JP (2) JP4510156B2 (de)
AT (1) ATE300293T1 (de)
BR (1) BR9808136A (de)
CA (1) CA2281946C (de)
DE (1) DE69830997T2 (de)
ES (1) ES2242273T3 (de)
HR (1) HRP980105A2 (de)
NO (1) NO325726B1 (de)
WO (1) WO1998038987A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DK1140027T3 (da) * 1998-12-23 2006-02-27 Alza Corp Doseringsformer indeholdende poröse partikler
US6387400B1 (en) * 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE12072T1 (de) * 1981-09-25 1985-03-15 Lacer Sa 1-azaxanthon zur therapeutischen verwendung, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen.
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
DD293499A5 (de) * 1989-06-06 1991-09-05 Arzneimittelwerk Dresden Gmbh,De Verfahren zur herstellung cyclosporinhaltiger galenischer formulierungen
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE69217200T2 (de) * 1991-11-04 1997-08-21 Fuisz Technologies Ltd Wasserlösliche abgabesysteme für hydrophobe flüssigkeiten
JP3121080B2 (ja) * 1991-12-19 2000-12-25 アール・ピー・シーラー コーポレイション カプセル封入用溶液
US5376688A (en) * 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
GB9302720D0 (en) * 1993-02-11 1993-03-24 Scherer Ltd R P Products in capsule form for use in aqueous solution

Also Published As

Publication number Publication date
EP0996436A4 (de) 2001-04-11
ES2242273T3 (es) 2005-11-01
NO994249L (no) 1999-11-03
JP2009286798A (ja) 2009-12-10
JP5563260B2 (ja) 2014-07-30
DE69830997T2 (de) 2006-02-09
ATE300293T1 (de) 2005-08-15
EP0996436B1 (de) 2005-07-27
BR9808136A (pt) 2000-03-28
HRP980105A2 (en) 1999-02-28
CA2281946A1 (en) 1998-09-11
NO325726B1 (no) 2008-07-07
WO1998038987A1 (en) 1998-09-11
JP4510156B2 (ja) 2010-07-21
CA2281946C (en) 2007-08-07
EP0996436A1 (de) 2000-05-03
JP2002513406A (ja) 2002-05-08
NO994249D0 (no) 1999-09-02

Similar Documents

Publication Publication Date Title
CA2152062A1 (en) Enhanced Solubility Pharmaceutical Solutions
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
UY23804A1 (es) Procedimiento de preparacion de medicamentos en forma de comprimidos con liberacion retardada de sustancia activa.
AU1227899A (en) Osmotic medicament releasing system
DE69909316D1 (de) Pharmazeutische formulierung mit omeprazol
RU94043809A (ru) Лекарственная композиция для релизконтроля
CA2327973A1 (en) Storage system for powdered pharmaceuticals, and inhaler equipped with this system
AU5084299A (en) Sustained release pharmaceutical preparation
AR012376A1 (es) Formulacion de gel para la aplicacion topica
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
ATE65023T1 (de) Pharmazeutische mittel.
IE871584L (en) Sustained release capsule.
CA2168732A1 (en) Gelatin Capsules Containing a Highly Concentrated Acetaminophen Solution
ATE260645T1 (de) Agitationsunabhängige pharmazeutische multiple- unit-retardzubereitungen und verfahren zu ihrer herstellung
AR011919A1 (es) FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA
IT1270239B (it) Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
CA2392545A1 (en) Pharmaceutical formulations for thyroid hormones
AU2084801A (en) Antiviral medication
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
DE69830997D1 (de) Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten
CA2255064A1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
PT1178787E (pt) Composicoes farmacologicas para administracao por via oral de floroglucinol e suas preparacoes
RU93004785A (ru) Твердые капсулы окфосфата цитарабина
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
DE69529079D1 (de) Codein enthaltende formulierungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

R082 Change of representative

Ref document number: 996436

Country of ref document: EP

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE